The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development by Pralay Mukhopadhyay, Hesham A. Abdullah, Joanna B. Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos, Sagar Lonial

“…Despite the 41% response rate and durable responses observed with belantamab mafodotin in the Phase III confirmatory DREAMM-3 trial, the marketing license for belantamab mafodotin was later withdrawn from US and European markets when the trial did not meet its primary endpoint of superiority for progression-free survival compared with pomalidomide and dexamethasone. This review reflects on key lessons arising from the clinical journey of belantamab mafodotin in RRMM. …”
Get full text

Protective effects and antioxidant mechanisms of lactobacillus combined with carnosine on the stomach and small intestine by Jian Qin, Ziyi Luo, Xu Yang, Yunqing Zhang, Huiying Li, Conghui Wang, Zhiqiang Zou, Yue Ma, Jing Ma, Daoyou Yue, Dipeng Zhao, Sen Qin, Rong Du

“…Here, we report the protective effects of LAB and/or CAR on the gastrointestinal tissues in normal or dexamethasone (Dex)-induced stress mice. The combination of LAB and CAR protected the structures of stomach and small intestine, alleviating the Dex-induced tissue damages. …”
Get full text

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma by Ka-Won Kang, Dae Sik Kim, Se Ryeon Lee, Mi Hwa Heo, Hyeon-Seok Eom, Jongheon Jung, Ji Hyun Lee, Sung-Hyun Kim, Youngil Koh, Chang-Ki Min, Seung Shin Lee, Sung-Nam Lim, Ho-Young Yhim, Myung-won Lee, Je-Jung Lee, Sung-Hoon Jung, Soo-Mee Bang, Kihyun Kim, the Korean Multiple Myeloma Working party [KMMWP]

“…Methods To determine whether maintenance therapy confers a survival benefit in the real world, we compared treatment outcomes according to the use and type of maintenance therapy in patients who underwent ASCT following frontline therapy with the triplet regimen of bortezomib, thalidomide, and dexamethasone for newly diagnosed multiple myeloma in 15 nationwide centers. …”
Get full text